K. Kuehlcke

发表

Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus.

I. Müller, D. von Laer, S. Naundorf, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene.

N. Selevsek, B. Fehse, D. von Laer, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Down-regulation of retroviral transgene expression during differentiation of progenitor-derived dendritic cells.

C. Baum, C. Lindemann, A. Schilz, 2002, Experimental hematology.

Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy

J. Utikal, U. Şahin, M. Diken, 2017 .

Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation

C. von Kalle, A. Ganser, R. Blasczyk, 2015, Journal of Translational Medicine.

Retroviral MDR1 gene transfer into marrow-engrafting human peripheral blood progenitor cells results in preferential transgene expression in the immature myeloid compartment rather than in mature myeloid progeny in vivo.

E. Buss, S. Naundorf, W. Zeller, 2006, Cytotherapy.

Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells

W. Ostertag, M. Hildinger, B. Schiedlmeier, 2001, Gene Therapy.

Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells.

E. Robinet, P. Tiberghien, C. Ferrand, 2004, Stem cells and development.

HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.

A. Hovnanian, W. Uckert, M. Leisegang, 2014, Human gene therapy. Clinical development.

A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration

A. Schambach, H. Hauser, D. Wirth, 2010, Gene Therapy.

Lentivirus-induced ‘Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

C. von Kalle, R. Gutzmer, F. Farzaneh, 2015, Gene Therapy.

Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.

C. von Kalle, B. Fehse, Johann Meyer, 2005, Blood.

Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions

A. Zander, A. Ho, A. Hotz-Wagenblatt, 2006, Bone Marrow Transplantation.

Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells.

A. Jauch, A. Ho, A. Benner, 2003, Blood.

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Felix Hermann, Christopher Baum, J. van Lunzen, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Clonal Analysis of Individual Marrow‐Repopulating Cells after Experimental Peripheral Blood Progenitor Cell Transplantation

E. Buss, S. Naundorf, J. Topaly, 2004, Stem cells.

Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation

C. von Kalle, A. Ganser, R. Blasczyk, 2015, Journal of Translational Medicine.

Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma

J. Utikal, U. Şahin, M. Diken, 2016 .

Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma

J. Utikal, D. Jäger, Ö. Türeci, 2018, Clinical Trials.

Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma

J. Utikal, U. Şahin, M. Diken, 2016 .